Isolevuglandins, oxidatively truncated phospholipids, and atherosclerosis
about
sameAs
Generation and biological activities of oxidized phospholipidsOxidative lipidomics coming of age: advances in analysis of oxidized phospholipids in physiology and pathologyPolyoxygenated cholesterol ester hydroperoxide activates TLR4 and SYK dependent signaling in macrophages.The role of oxidized phospholipids in atherosclerosis.GRP78 is a novel receptor initiating a vascular barrier protective response to oxidized phospholipidsMD-2 binds cholesterol.Endothelial cell regulation by phospholipid oxidation products.Isolevuglandins covalently modify phosphatidylethanolamines in vivo: detection and quantitative analysis of hydroxylactam adducts.Advances in methods for the determination of biologically relevant lipid peroxidation products.Lysophosphatidic acid effects on atherosclerosis and thrombosis.An inter-laboratory validation of methods of lipid peroxidation measurement in UVA-treated human plasma samples.Protein targets of oxidized phospholipids in endothelial cells.Total Synthesis Confirms the Molecular Structure Proposed for Oxidized Levuglandin D2.Phospholipid hydroxyalkenals, a subset of recently discovered endogenous CD36 ligands, spontaneously generate novel furan-containing phospholipids lacking CD36 binding activity in vivo.
P2860
Q28389691-113FF678-83B1-4828-BFB0-1D8E069803AEQ28397441-43C471AD-8E39-4018-8641-141DF599A06EQ28537901-0E7B82E9-75A1-4175-8065-4E3F2300DD97Q30436606-1474CDBA-F0DE-4A08-B9AC-1CC796F431F6Q33811945-2E95FAE5-F7BF-4654-AE7D-EF2DF49237BFQ37025111-ED495F14-9D0F-4D63-B372-01E63D491965Q37156030-67CD39F8-9E76-45DA-987D-D9071B7BCF98Q37438010-87181B69-C02A-4E73-A079-07ADF43313FBQ37788232-C76D1A9C-718B-41B7-9791-C23AC108DD99Q39608397-AC8BDA7B-4FA4-4C39-A295-64EA0361509DQ42909162-30494BAE-81AB-48B7-B116-47FFBBE792CDQ46491468-8AAE5A03-C06C-4460-8139-C719431FE6A7Q48239770-CC535D4F-3D01-4A07-B19E-6AD890DC84D4Q48447481-B1739524-9E90-48BF-99F5-5E879D67F421
P2860
Isolevuglandins, oxidatively truncated phospholipids, and atherosclerosis
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Isolevuglandins, oxidatively truncated phospholipids, and atherosclerosis
@ast
Isolevuglandins, oxidatively truncated phospholipids, and atherosclerosis
@en
Isolevuglandins, oxidatively truncated phospholipids, and atherosclerosis
@nl
type
label
Isolevuglandins, oxidatively truncated phospholipids, and atherosclerosis
@ast
Isolevuglandins, oxidatively truncated phospholipids, and atherosclerosis
@en
Isolevuglandins, oxidatively truncated phospholipids, and atherosclerosis
@nl
altLabel
Isolevuglandins, Oxidatively Truncated Phospholipids, and Atherosclerosis
@en
prefLabel
Isolevuglandins, oxidatively truncated phospholipids, and atherosclerosis
@ast
Isolevuglandins, oxidatively truncated phospholipids, and atherosclerosis
@en
Isolevuglandins, oxidatively truncated phospholipids, and atherosclerosis
@nl
P2860
P356
P1476
Isolevuglandins, Oxidatively Truncated Phospholipids, and Atherosclerosis
@en
Isolevuglandins, oxidatively truncated phospholipids, and atherosclerosis
@en
P2093
ROBERT G. SALOMON
Robert G Salomon
P2860
P356
10.1196/ANNALS.1333.040
P407
P577
2005-06-01T00:00:00Z